Mindera Health™ Announces Contract With General Services Administration®
San Diego, CA, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Mindera Health today announced that the General Services Administration (GSA) has granted a 5 year contract award to Mindera Health enabling access to their proprietary technology, Mind.Px.
- San Diego, CA, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Mindera Health today announced that the General Services Administration (GSA) has granted a 5 year contract award to Mindera Health enabling access to their proprietary technology, Mind.Px.
- The Mind.Px test is the first and only test that provides a personalized approach selecting the class of biologic therapy a patient with plaque psoriasis is most likely to respond to.
- The decision is effective today and enables access to Mind.Px for those eligible for treatment at government-affiliated facilities including the over 9.6 million veterans, active duty, retirees and their families that are served by the Veteran’s Administration Health System and Department of Defense Medical Treatment Facilities, and others.
- “Mind.Px addresses an unmet need in the effective management of plaque psoriasis patients by informing the selection of the most efficacious class of biologic therapy for a particular patient.” said Dr. Jeffrey Travers, Professor and Chair of Pharmacology and Toxicology and Professor of Dermatology at the Boonshoft School of Medicine at Wright State University and VA investigator at the Dayton VA Medical Center with no formal ties to Mindera Health.